Helen Louise Collins, serving as the Chief Medical Officer for Enliven Therapeutics, Inc. (NASDAQ: ELVN), executed a series of transactions involving the company's common stock on June 17, 2026. The primary activity involved the sale of 4,900 shares, generating a total proceeds amount of $219,016. The execution of these sales occurred at varying prices, specifically ranging from $42.295 to $44.95 per share.
Concurrent with the sales, Ms. Collins acquired an additional 5,000 shares of Enliven Therapeutics common stock through the exercise of stock options. The exercise price for these options was established at $2.48 per share, resulting in a total cost of $12,400 for the acquisition. The documentation indicates that these options were fully vested and exercisable at the time of the transaction.
Following the option exercise, Ms. Collins proceeded to sell shares through multiple distinct trades. The breakdown of these sales includes 1,268 shares sold at a weighted average price of $42.827, 2,599 shares sold at a weighted average price of $43.8701, and 1,133 shares sold at a weighted average price of $44.743. The aggregate prices for these specific sales transactions fell within the broader range of $42.295 to $44.95 per share.
The timing of these insider transactions coincides with Enliven Therapeutics stock trading in close proximity to its 52-week high of $48.53. The stock has experienced substantial appreciation, recording gains of 112% over the past year and 152% over the preceding six-month period. According to analysis provided by InvestingPro, the stock is currently assessed as overvalued based on its Fair Value assessment. The current share price stands at $45.96.
All reported transactions were conducted in accordance with a Rule 10b5-1 trading plan. Ms. Collins adopted this pre-arranged plan on October 19, 2025. Following the completion of these activities, Ms. Collins maintains a direct holding of 25,000 shares of Enliven Therapeutics common stock. This holding includes some restricted stock units (RSUs). Additionally, she holds 121,268 stock options.
In broader corporate developments, Enliven Therapeutics has successfully closed a $460 million public offering. This upsized offering resulted in the sale of 10,533,334 shares of common stock at a price of $37.50 per share. The total volume included an additional 1,600,000 shares derived from the underwriters' full exercise of their option. The company also issued pre-funded warrants for 1,733,333 shares, priced at $37.499 per warrant.
Earlier in the process, Enliven Therapeutics had announced a $250 million stock offering. This initial announcement granted underwriters a 30-day option to purchase up to an additional $37.5 million in common stock. The company's stock price data indicates a current value of 45.96, reflecting a change of +0.860 (+1.91%) at close. After hours trading shows a price of 45.00, representing a change of -0.960 (-2.09%).
Enliven Therapeutics also reported positive results from its Phase 1 ENABLE trial concerning the leukemia drug candidate ELVN-001. The trial data revealed a 61% overall major molecular response. Additionally, 48% of participants achieved this response by 24 weeks within the 80 mg once-daily Phase 1b cohort. The trial enrolled a total of 161 patients. Data indicates that 76% of participants remained on the study, with a median treatment duration of 35 weeks.
These clinical developments are part of Enliven Therapeutics' ongoing efforts to advance its clinical-stage biopharmaceutical endeavors. The company continues to navigate the intersection of clinical validation and capital markets activity.